Gastrointestinal Neoplasm Clinical Trials

4 recruiting

Gastrointestinal Neoplasm Trials at a Glance

23 actively recruiting trials for gastrointestinal neoplasm are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Not Applicable with 8 trials, with the heaviest enrollment activity in Houston, Barcelona, and Villejuif. Lead sponsors running gastrointestinal neoplasm studies include GlaxoSmithKline, Baylor College of Medicine, and Assistance Publique - Hôpitaux de Paris.

Browse gastrointestinal neoplasm trials by phase

Treatments under study

About Gastrointestinal Neoplasm Clinical Trials

Looking for clinical trials for Gastrointestinal Neoplasm? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastrointestinal Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastrointestinal Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Phase 3

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Colorectal NeoplasmsNeoplasms by SiteGastrointestinal Neoplasms+7 more
Pfizer800 enrolled156 locationsNCT07222800
Recruiting
Phase 1

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

Colorectal NeoplasmsGastrointestinal Neoplasms
Janssen Research & Development, LLC220 enrolled10 locationsNCT06663319
Recruiting
Phase 3

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

Gastrointestinal Neoplasms
GlaxoSmithKline450 enrolled84 locationsNCT07218926
Recruiting

Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions

Gastrointestinal NeoplasmsBenign Neoplasm of Intestinal Tract
California Pacific Medical Center Research Institute8,000 enrolled1 locationNCT01750619
Recruiting
Not Applicable

Traction vs. No Traction in Colonic ESD

Gastrointestinal Neoplasm
Baylor College of Medicine150 enrolled2 locationsNCT06159634
Recruiting
Not Applicable

Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection

Gastrointestinal Neoplasm
Baylor College of Medicine66 enrolled2 locationsNCT06134687
Recruiting

Impact of Oral Versus Intravenous 5-FU-Based Adjuvant Regimens on Sleep Quality and Depression in Patients With Gastrointestinal Cancers

Gastrointestinal Neoplasms
Ankara Etlik City Hospital82 enrolled3 locationsNCT06996483
Recruiting
Not Applicable

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Liver CancerBiliary Tract CancerColon Cancer+76 more
Cedars-Sinai Medical Center360 enrolled1 locationNCT04907643
Recruiting
Not Applicable

Telephone Support in Advanced Gastrointestinal Cancer

Caregiver BurdenGastrointestinal Neoplasm Malignant
Indiana University488 enrolled4 locationsNCT06532877
Recruiting
Phase 1

A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects

Antineoplastic AgentsGastrointestinal NeoplasmsFecal Microbiota Transplantation (FMT)
Second Affiliated Hospital, School of Medicine, Zhejiang University90 enrolled1 locationNCT07319364
Recruiting

Evaluation of Neoplasia With Artificial Intelligence in Gastrointestinal Endoscopy

Gastrointestinal Neoplasms
Portsmouth Hospitals NHS Trust1,650 enrolled1 locationNCT04937647
Recruiting
Phase 1Phase 2

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

Gastrointestinal Neoplasms
GlaxoSmithKline320 enrolled47 locationsNCT06885034
Recruiting
Phase 1

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Metastatic CancerGastrointestinal NeoplasmsGastrointestinal Diseases+2 more
IDRX, Inc., a wholly owned subsidiary of GSK, LLC278 enrolled30 locationsNCT05489237
Recruiting
Not Applicable

PPG vs. ICG in Gastrointestinal Resections

Gastric Cancer (GC)Postoperative ComplicationsGastrointestinal Neoplasms+2 more
Saint Petersburg State University, Russia200 enrolled3 locationsNCT06222645
Recruiting

AI for Onsite Cytology Evaluation in Endoscopic Ultrasound

Gastrointestinal NeoplasmMass Lesion
Orlando Health, Inc.200 enrolled1 locationNCT07228689
Recruiting
Phase 2

The ctDNA-RECIST Trial Part One

Gastrointestinal Neoplasm
Karen-Lise Garm Spindler167 enrolled2 locationsNCT06562348
Recruiting
Phase 2

SGM-101 in Colorectal Brain Metastases.

Colorectal NeoplasmsGastrointestinal CancerBrain Metastases+10 more
Leiden University Medical Center10 enrolled2 locationsNCT04755920
Recruiting
Not Applicable

Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.

Head and Neck NeoplasmsEsophageal NeoplasmsNeoplasms+6 more
Taipei Veterans General Hospital, Taiwan20 enrolled1 locationNCT06365866
Recruiting
Phase 2

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

Gastric CancerGastroesophageal-junction CancerCarcinoma+4 more
The First Affiliated Hospital with Nanjing Medical University80 enrolled1 locationNCT05494060
Recruiting
Not Applicable

Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models

Gastrointestinal Neoplasm Malignant
Chinese Academy of Sciences400 enrolled7 locationsNCT06002425